Advanced Biomed Inc. (ADVB)

NCM – Real vaqt narxi. Valyuta: USD

5.23

+0.22 (4.39%)

Yopilishda: May 12, 2026, 4:00 PM EDT

18.02.2026

Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Tainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced a reverse stock split of the Company's issued and outstanding common stock at a ratio of 1 for 20 shares (the “Reverse Split”), which will take effect at the open of The Nasdaq Stock Market (“Nasdaq”) on February 20, 2026. In accordance with Section 78.320.2 of the Nevada Revised Statutes, on January 12, 2026, the holders of a majority of the outstanding voting power of the Company approved by written consent a reverse stock split of the Company's issued and outstanding shares of common stock, at a ratio of not less than 1 for 2 and not more than 1 for 100 shares, with the final ratio and timing of implementation to be determined by the board in its sole discretion, and authorized the board to effect such reverse stock split at any time thereafter.

13.02.2026

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the “Agreement”) with Chi‑Mei Medical Center to initiate a 120‑case feasibility study designed to evaluate the predictive accuracy of the Company's A+PerfusC™, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro.

30.12.2025

Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary

Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced that on December 23, 2025, it entered into an agreement (the “Agreement”) with an unrelated third party, Wei Ha Hui (the “Buyer”), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the “Hong Kong Subsidiary”), for an aggregate purchase price of US$23,000 based on a valuation report commissioned by the Company, subject to the terms and conditions set forth in the Agreement.

Videolar

No Data

There is no data to display

Press-relizlar

18.02.2026

Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

13.02.2026

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

30.12.2025

Advanced Biomed Inc. (ADVB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Advanced Biomed Inc. (ADVB)

Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary

Videolar

No Data

Press-relizlar

Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary

Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary

Videolar

No Data

Press-relizlar

Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary

Search stocks

Advanced Biomed Inc. (ADVB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Advanced Biomed Inc. (ADVB)

Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary

Videolar

No Data

Press-relizlar

Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary

Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary

Videolar

No Data

Press-relizlar

Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary